WallStreetZenWallStreetZen

NASDAQ: LIFE
Atyr Pharma Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for LIFE

Based on 4 analysts offering 12 month price targets for Atyr Pharma Inc.
Min Forecast
$14.00+386.11%
Avg Forecast
$22.75+689.93%
Max Forecast
$35.00+1,115.28%

Should I buy or sell LIFE stock?

Based on 4 analysts offering ratings for Atyr Pharma Inc.
Strong Buy
Strong Buy
1 analysts 25%
Buy
3 analysts 75%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LIFE stock forecasts and price targets.

LIFE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Piper Sandler
Top 8%
93
Strong BuyMaintains$14.00+386.11%2022-08-16Find out why
HC Wainwright & Co.
Bottom 26%
26
BuyMaintains$35.00+1,115.28%2022-07-21
RBC Capital
Bottom 33%
33
BuyMaintains$20.00+594.44%2022-05-10
RBC Capital
Bottom 25%
25
BuyInitiates Coverage On$22.00+663.89%2021-10-12

1 of 1

Forecast return on equity

Is LIFE forecast to generate an efficient return?
Company
-40.31%
Industry
22.46%
Market
122.06%
LIFE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is LIFE forecast to generate an efficient return on assets?
Company
-36.37%
Industry
13.57%
LIFE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

LIFE earnings per share forecast

What is LIFE's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$1.81
Avg 2 year Forecast
-$1.80
Avg 3 year Forecast
-$1.51

LIFE revenue forecast

What is LIFE's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$4.0M
Avg 2 year Forecast
$11.5M
Avg 3 year Forecast
$17.5M

LIFE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LIFE$2.88$22.75+689.93%Strong Buy
CLSD$1.37$7.50+447.45%Buy
HCWB$2.29$7.00+205.68%Strong Buy
ASMB$1.69$12.00+610.06%Strong Buy
RPHM$3.34$27.50+723.35%Strong Buy

Atyr Pharma Stock Forecast FAQ

Is Atyr Pharma Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: LIFE) stock is to Strong Buy LIFE stock.

Out of 4 analysts, 1 (25%) are recommending LIFE as a Strong Buy, 3 (75%) are recommending LIFE as a Buy, 0 (0%) are recommending LIFE as a Hold, 0 (0%) are recommending LIFE as a Sell, and 0 (0%) are recommending LIFE as a Strong Sell.

If you're new to stock investing, here's how to buy Atyr Pharma stock.

What is LIFE's earnings growth forecast for 2022-2024?

(NASDAQ: LIFE) Atyr Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Atyr Pharma's earnings in 2022 is -$40,799,000.On average, 3 Wall Street analysts forecast LIFE's earnings for 2022 to be -$51,811,333, with the lowest LIFE earnings forecast at -$53,815,086, and the highest LIFE earnings forecast at -$50,380,081. On average, 3 Wall Street analysts forecast LIFE's earnings for 2023 to be -$51,525,083, with the lowest LIFE earnings forecast at -$71,562,615, and the highest LIFE earnings forecast at -$40,933,816.

In 2024, LIFE is forecast to generate -$43,223,819 in earnings, with the lowest earnings forecast at -$44,655,072 and the highest earnings forecast at -$42,078,818.

What is LIFE's revenue growth forecast for 2022-2024?

(NASDAQ: LIFE) Atyr Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.53%.

Atyr Pharma's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast LIFE's revenue for 2022 to be $114,500,184, with the lowest LIFE revenue forecast at $114,500,184, and the highest LIFE revenue forecast at $114,500,184. On average, 2 Wall Street analysts forecast LIFE's revenue for 2023 to be $329,188,029, with the lowest LIFE revenue forecast at $143,125,230, and the highest LIFE revenue forecast at $515,250,828.

In 2024, LIFE is forecast to generate $500,938,305 in revenue, with the lowest revenue forecast at $286,250,460 and the highest revenue forecast at $715,626,150.

What is LIFE's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: LIFE) forecast ROA is -36.37%, which is lower than the forecast US Biotechnology industry average of 13.57%.

What is LIFE's Price Target?

According to 4 Wall Street analysts that have issued a 1 year LIFE price target, the average LIFE price target is $22.75, with the highest LIFE stock price forecast at $35.00 and the lowest LIFE stock price forecast at $14.00.

On average, Wall Street analysts predict that Atyr Pharma's share price could reach $22.75 by Aug 16, 2023. The average Atyr Pharma stock price prediction forecasts a potential upside of 689.93% from the current LIFE share price of $2.88.

What is LIFE's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: LIFE) Atyr Pharma's current Earnings Per Share (EPS) is -$1.51. On average, analysts forecast that LIFE's EPS will be -$1.81 for 2022, with the lowest EPS forecast at -$1.88, and the highest EPS forecast at -$1.76. On average, analysts forecast that LIFE's EPS will be -$1.80 for 2023, with the lowest EPS forecast at -$2.50, and the highest EPS forecast at -$1.43. In 2024, LIFE's EPS is forecast to hit -$1.51 (min: -$1.56, max: -$1.47).

What is LIFE's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: LIFE) forecast ROE is -40.31%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.